

<div style="display: flex; align-items: center;"><div style="writing-mode: vertical-rl; transform: rotate(180deg); font-size: small; margin-right: 5px;">18334 U.S. PTO</div><div>UTILITY PATENT APPLICATION TRANSMITTAL (Small Entity) <i>(Only for new nonprovisional applications under 37 CFR 1.53(b))</i></div></div>	<div style="border: 1px solid black; padding: 2px; margin-bottom: 2px;">Docket No. 02940232AA</div> <div style="border: 1px solid black; padding: 2px;">Total Pages in this Submission</div>
	<u>TO THE COMMISSIONER FOR PATENTS</u> Mail Stop Patent Application P.O. Box 1450 Alexandria, VA 22313-1450
<p>Transmitted herewith for filing under 35 U.S.C. 111(a) and 37 C.F.R. 1.53(b) is a new utility patent application for an invention entitled:</p> <div style="border: 1px solid black; padding: 5px; min-height: 40px;">SULFONAMIDE CANNABINOID AGONISTS AND ANTAGONISTS</div>	
<p>and invented by:</p> <div style="border: 1px solid black; padding: 5px; min-height: 40px;">Billy R. Martin, Raj K. Razdan, Roger G. Pertwee</div>	
<p>If a CONTINUATION APPLICATION, check appropriate box and supply the requisite information:</p> <div style="display: flex; justify-content: space-between; align-items: flex-start;"><div><input type="checkbox"/> Continuation <input type="checkbox"/> Divisional <input type="checkbox"/> Continuation-in-part (CIP)</div><div>of prior application No.: _____</div></div> <p>Which is a:</p> <div style="display: flex; justify-content: space-between; align-items: flex-start;"><div><input type="checkbox"/> Continuation <input type="checkbox"/> Divisional <input type="checkbox"/> Continuation-in-part (CIP)</div><div>of prior application No.: _____</div></div> <p>Which is a:</p> <div style="display: flex; justify-content: space-between; align-items: flex-start;"><div><input type="checkbox"/> Continuation <input type="checkbox"/> Divisional <input type="checkbox"/> Continuation-in-part (CIP)</div><div>of prior application No.: _____</div></div>	
<p>Enclosed are:</p> <p style="text-align: center;">Application Elements</p> <div style="margin-left: 20px;"><p>1. <input type="checkbox"/> Filing fee as calculated and transmitted as described below</p><p>2. <input checked="" type="checkbox"/> Specification having <u>31</u> pages and including the following:</p><div style="margin-left: 20px;"><p>a. <input checked="" type="checkbox"/> Descriptive Title of the Invention</p><p>b. <input type="checkbox"/> Cross References to Related Applications <i>(if applicable)</i></p><p>c. <input checked="" type="checkbox"/> Statement Regarding Federally-sponsored Research/Development <i>(if applicable)</i></p><p>d. <input type="checkbox"/> Reference to Sequence Listing, a Table, or a Computer Program Listing Appendix</p><p>e. <input checked="" type="checkbox"/> Background of the Invention</p><p>f. <input checked="" type="checkbox"/> Brief Summary of the Invention</p><p>g. <input checked="" type="checkbox"/> Brief Description of the Drawings <i>(if filed)</i></p><p>h. <input checked="" type="checkbox"/> Detailed Description</p><p>i. <input checked="" type="checkbox"/> Claim(s) as Classified Below</p><p>j. <input checked="" type="checkbox"/> Abstract of the Disclosure</p></div></div>	

UTILITY PATENT APPLICATION TRANSMITTAL
(Small Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No.
02940232AA

Total Pages in this Submission

Application Elements (Continued)

3. ☒ Drawing(s) *(when necessary as prescribed by 35 USC 113)*
- a. ☐ Formal Number of Sheets _____
- b. ☒ Informal Number of Sheets 4
4. ☒ Oath or Declaration
- a. ☐ Newly executed *(original or copy)* ☒ Unexecuted
- b. ☐ Copy from a prior application (37 CFR 1.63(d)) *(for continuation/divisional application only)*
- c. ☒ With Power of Attorney ☐ Without Power of Attorney
- d. ☐ **DELETION OF INVENTOR(S)**
Signed statement attached deleting inventor(s) named in the prior application,
see 37 C.F.R. 1.63(d)(2) and 1.33(b).
5. ☐ Incorporation By Reference *(usable if Box 4b is checked)*
The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 4b, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.
6. ☐ CD ROM or CD-R in duplicate, large table or Computer Program (Appendix)
7. ☐ Application Data Sheet (See 37 CFR 1.76)
8. ☐ Nucleotide and/or Amino Acid Sequence Submission *(if applicable, all must be included)*
- a. ☐ Computer Readable Form (CFR)
- b. ☐ Specification Sequence Listing on:
- i. ☐ CD-ROM or CD-R (2 copies); or
- ii. ☐ Paper
- c. ☐ Statement(s) Verifying Identical Paper and Computer Readable Copy

Accompanying Application Parts

9. ☐ Assignment Papers (cover sheet & document(s))
10. ☐ 37 CFR 3.73(B) Statement (when there is an assignee)
11. ☐ English Translation Document (if applicable)
12. ☐ Information Disclosure Statement/PTO-1449 ☐ Copies of IDS Citations
13. ☐ Preliminary Amendment
14. ☒ Return Receipt Postcard (MPEP 503) (Should be specifically itemized)
15. ☐ Certified Copy of Priority Document(s) (if foreign priority is claimed)
16. ☐ Certificate of Mailing
- ☐ First Class ☐ Express Mail *(Specify Label No.):* **HAND DELIVERED**

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Total Pages in this Submission

17. ☒ Applicant claims small entity status. See 37 CFR 1.27.

☐ (Optional) Small Entity Statement(s) - Specify Number of Statements Submitted:

18. ☐ Additional Enclosures (*please identify below*):

19. ☐ Pursuant to 35 U.S.C. 122(b)(2), Applicant hereby requests that this patent application not be published pursuant to 35 U.S.C. 122(b)(1). Applicant hereby certifies that the invention disclosed in this application has not and will not be the subject of an application filed in another country, or under a multilateral international agreement, that requires publication of applications 18 months after filing of the application.

An applicant who makes a request not to publish, but who subsequently files in a foreign country or under a multilateral international agreement specified in 35 U.S.C. 122(b)(2)(B)(i), must notify the Director of such filing not later than 45 days after the date of the filing of such foreign or international application. A failure of the applicant to provide such notice within the prescribed period shall result in the application being regarded as abandoned, unless it is shown to the satisfaction of the Director that the delay in submitting the notice was unintentional.

UTILITY PATENT APPLICATION TRANSMITTAL
(Small Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No.
02940232AA

Total Pages in this Submission

Fee Calculation and Transmittal

CLAIMS AS FILED

For	#Filed	#Allowed	#Extra	Rate	Fee
Total Claims	16	- 20 =	0	x \$9.00	\$0.00
Indep. Claims	11	- 3 =	8	x \$42.00	\$336.00
Multiple Dependent Claims (check if applicable) <input type="checkbox"/>					\$0.00
BASIC FEE					\$375.00
OTHER FEE (specify purpose)					\$0.00
TOTAL FILING FEE					\$711.00


- ☐ A check in the amount of _____ to cover the filing fee is enclosed.
- ☐ The Director is hereby authorized to charge and credit Deposit Account No. _____ as described below.
- ☐ Charge the amount of _____ as filing fee.
- ☐ Credit any overpayment.
- ☐ Charge any additional filing fees required under 37 C.F.R. 1.16 and 1.17.
- ☐ Charge the issue fee set in 37 C.F.R. 1.18 at the mailing of the Notice of Allowance, pursuant to 37 C.F.R. 1.311(b).

Dated: June 24, 2003



30743

PATENT TRADEMARK OFFICE


Signature

Ruth Tyler-Cross
Reg No. 45,922
Whitham, Curtis & Christofferson, P.C.
11491 Sunset Hills Road, Suite 340
Reston, Virginia 20190
703-787-9400

CC: